This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Townsend, K. Articles by Hewison, M. Search for Related Content PubMed PubMed Citation Articles by Townsend, K. Articles by Hewison, M.

Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue

Authors' Affiliations: ¹ Division of Medical Sciences, Institute of Biomedical Research, Endocrinology and Metabolism, University of Birmingham, Birmingham, United Kingdom and ² Department of Cellular and Molecular Medicine, St. George's Hospital Medical School, London, United Kingdom

Requests for reprints: Martin Hewison, Division of Medical Sciences, Institute of Biomedical Research, Endocrinology and Metabolism, University of Birmingham, Birmingham B15 2TT, United Kingdom. Phone: 44-121-414-3776; Fax: 44-121-415-8712; E-mail: M.Hewison{at}bham.ac.uk.

Purpose: Vitamin D seems to exert a protective effect against common cancers, although this does not correlate with circulating levels of active 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], indicating a more localized activation of vitamin D. The aim of this study was to investigate the significance of this in breast cancer.

Experimental Design: Quantitative reverse transcription-PCR analysis of mRNA expression was carried out for the vitamin D–activating enzyme 1-hydroxylase, the catabolic enzyme 24-hydroxylase, and the vitamin D receptor in 41 tumors and paired nonneoplastic tissue as well as breast cancer cell lines. Immunohistochemistry was used to assess 1-hydroxylase protein expression, and enzyme assays were used to quantify vitamin D metabolism.

Results: Expression of mRNA for 1-hydroxylase (27-fold; P < 5 x 10^–11), vitamin D receptor (7-fold; P < 1.5 x 10^–8), and 24-hydroxylase (4-fold; P < 0.02) was higher in breast tumors. 1-Hydroxylase enzyme activity was also higher in tumors (44.3 ± 11.4 versus 12.4 ± 4.8 fmol/h/mg protein in nonneoplastic tissue; P < 0.05). However, production of inactive 1,24,25-trihydroxyvitamin D₃ was also significantly higher in tumors (84.8 ± 11.7 versus 33.6 ± 8.5 fmol/h/mg protein; P < 0.01). Antisense inhibition of 24-hydroxylase in vitro increased antiproliferative responses to 1,25(OH)₂D₃.

Conclusion: These data indicate that the vitamin D–activating enzyme 1-hydroxylase is up-regulated in breast tumors. However, dysregulated expression of 24-hydroxylase seems to abrogate the effects of local 1,25(OH)₂D₃ production in tumors by catalyzing catabolism to less active vitamin D metabolites. The enzymes involved in autocrine metabolism of vitamin D in breast tissue may therefore provide important targets for both the prevention and treatment of breast cancer.

Key Words: vitamin D • breast cancer • 1-hydroxylase • 24-hydroxylase • vitamin D receptor

This article has been cited by other articles:

				P. J. Goodwin Vitamin D in Cancer Patients: Above All, Do No Harm J. Clin. Oncol., May 1, 2009; 27(13): 2117 - 2119. [Full Text] [PDF]

				G. Cao, Z. Gu, Y. Ren, L. Shu, C. Tao, A. Karaplis, D. Goltzman, and D. Miao Parathyroid Hormone Contributes to Regulating Milk Calcium Content and Modulates Neonatal Bone Formation Cooperatively with Calcium Endocrinology, February 1, 2009; 150(2): 561 - 569. [Abstract] [Full Text] [PDF]

				F. R. Perez-Lopez, P. Chedraui, and J. Haya Review Article: Vitamin D Acquisition and Breast Cancer Risk Reproductive Sciences, January 1, 2009; 16(1): 7 - 19. [Abstract] [PDF]

				J. D. McKay, M. L. McCullough, R. G. Ziegler, P. Kraft, B. S. Saltzman, E. Riboli, A. Barricarte, C. D. Berg, G. Bergland, S. Bingham, et al. Vitamin D Receptor Polymorphisms and Breast Cancer Risk: Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 297 - 305. [Abstract] [Full Text] [PDF]

				S. Hansdottir, M. M. Monick, S. L. Hinde, N. Lovan, D. C. Look, and G. W. Hunninghake Respiratory Epithelial Cells Convert Inactive Vitamin D to Its Active Form: Potential Effects on Host Defense J. Immunol., November 15, 2008; 181(10): 7090 - 7099. [Abstract] [Full Text] [PDF]

				K. M. Blackmore, M. Lesosky, H. Barnett, J. M. Raboud, R. Vieth, and J. A. Knight Vitamin D From Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer Am. J. Epidemiol., October 15, 2008; 168(8): 915 - 924. [Abstract] [Full Text] [PDF]

				S. D. Conzen Minireview: Nuclear Receptors and Breast Cancer Mol. Endocrinol., October 1, 2008; 22(10): 2215 - 2228. [Abstract] [Full Text] [PDF]

				E. M. John, G. G. Schwartz, J. Koo, W. Wang, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Breast Cancer Risk in a Multiethnic Population Am. J. Epidemiol., December 15, 2007; 166(12): 1409 - 1419. [Abstract] [Full Text] [PDF]

				R F Chun, M Gacad, L Nguyen, M Hewison, and J S Adams Co-chaperone potentiation of vitamin D receptor-mediated transactivation: a role for Bcl2-associated athanogene-1 as an intracellular-binding protein for 1,25-dihydroxyvitamin D3 J. Mol. Endocrinol., August 1, 2007; 39(2): 81 - 89. [Abstract] [Full Text] [PDF]

				S. Wu, S. Ren, L. Nguyen, J. S. Adams, and M. Hewison Splice Variants of the CYP27b1 Gene and the Regulation of 1,25-Dihydroxyvitamin D3 Production Endocrinology, July 1, 2007; 148(7): 3410 - 3418. [Abstract] [Full Text] [PDF]

				J. A. Knight, M. Lesosky, H. Barnett, J. M. Raboud, and R. Vieth Vitamin D and Reduced Risk of Breast Cancer: A Population-Based Case-Control Study Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 422 - 429. [Abstract] [Full Text] [PDF]

				D. Lechner, T. Manhardt, E. Bajna, G. H. Posner, and H. S. Cross A 24-Phenylsulfone Analog of Vitamin D Inhibits 1{alpha},25-Dihydroxyvitamin D3 Degradation in Vitamin D Metabolism-Competent Cells J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1119 - 1126. [Abstract] [Full Text] [PDF]

				C Palmieri, T MacGregor, S Girgis, and D Vigushin Serum 25-hydroxyvitamin D levels in early and advanced breast cancer J. Clin. Pathol., December 1, 2006; 59(12): 1334 - 1336. [Abstract] [Full Text] [PDF]

				S. Sundaram, M. J. Beckman, A. Bajwa, J. Wei, K. M. Smith, G. H. Posner, and D. A. Gewirtz QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2806 - 2814. [Abstract] [Full Text] [PDF]

				M. J. Rowling, C. M. Kemmis, D. A. Taffany, and J. Welsh Megalin-Mediated Endocytosis of Vitamin D Binding Protein Correlates with 25-Hydroxycholecalciferol Actions in Human Mammary Cells J. Nutr., November 1, 2006; 136(11): 2754 - 2759. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]

				C. M. Kemmis, S. M. Salvador, K. M. Smith, and J. Welsh Human Mammary Epithelial Cells Express CYP27B1 and Are Growth Inhibited by 25-Hydroxyvitamin D-3, the Major Circulating Form of Vitamin D-3 J. Nutr., April 1, 2006; 136(4): 887 - 892. [Abstract] [Full Text] [PDF]

				M. L. McCullough, C. Rodriguez, W. R. Diver, H. S. Feigelson, V. L. Stevens, M. J. Thun, and E. E. Calle Dairy, Calcium, and Vitamin D Intake and Postmenopausal Breast Cancer Risk in the Cancer Prevention Study II Nutrition Cohort Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2898 - 2904. [Abstract] [Full Text] [PDF]